 |
|
|
|
|
|
|
| Article 1 to 9 out of 9 concerning Lab21 Ltd
|
-
Lab21 expands its range of cardiovascular genetic tests with Clinical Data, Inc.
(29 Sep 2008)
Lab21 announced the expansion of its portfolio of genetic tests for inherited cardiac syndromes. Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc., Lab21 offers exclusive U.K. and Ireland access to the Familion® ...
-
Lab21 acquires NPTech Ltd and appoints corporate advisors for European M&A activity
(27 Mar 2008)
Lab21 has acquired NPTech Ltd, an independent clinical laboratory company providing diagnostic testing services for the NHS and private healthcare providers in the UK and parts of Europe. The acquisition of NPTech, in an undisclosed financial ...
-
Predictive genetic test for bowel cancer treatment is introduced in the UK
(20 Mar 2008)
Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are ...
-
Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
(25 Feb 2008)
Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland.The test, known as CRS7, ...
-
Lab21 launches cancer gene testing service
(28 Jan 2008)
Lab21 announced the launch of a cancer gene testing service from its Cambridge laboratories. Lab21 is providing a test for analysis of the K-ras gene. K-ras plays an important role in cell growth regulation and the proliferation of cancer cells. In ...
-
Lab21 appoints new CEO
(07 Nov 2007)
Lab21 has announced the appointment of Graham Mullis as its new CEO. Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at ...
-
Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic
(15 Oct 2007)
Lab 21 announced that it has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidized low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart ...
-
New syphilis test provides quicker and easier diagnosis
(16 Aug 2007)
Newmarket Laboratories, part of the Lab21 Group has developed a new diagnostic test for syphilis which is rapid, accurate and easy to use, according to the company. The new syphilis IgM antibody test uses recombinant antigens, which have a high ...
-
Lab21 secures additional IP for Hepatitis C diagnostics
(21 Oct 2005)
Lab 21 announced that it has completed an agreement to exclusively license the Hepatitis C (HCV) diagnostic technology and associated patent applications of Dr. Carol Holland (TROY, MI, USA). The deal was brokered by UTEK-EKMS (CAMBRIDGE, MA, USA), ...
|
|
|
|
|
Top
analytica
analytica China
analytica Vietnam
analytica Anacon